Therapy Areas: Inflammatory Diseases
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
15 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) reported on Wednesday that it has completed the acquisition of 35Pharma Inc, a Canada-based clinical-stage biopharmaceutical co...
Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting
15 April 2026 - Mestag Therapeutics, a UK-based biotech company using fibroblast immunology to develop treatments for patients with cancer and inflammatory disease, announced on Tuesday that it has be...
Trellus Health renews licensing agreement with Pfizer
13 April 2026 - Healthcare company Trellus Health plc (AIM: TRLS) announced on Monday that it has renewed its licensing agreement with biopharmaceutical company Pfizer Inc, extending the use of its pa...
EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria
13 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) announced on Monday that they have rece...
GSK secures China approval for Exdensur to treat nasal polyp condition
8 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) revealed on Wednesday that it has received approval from China's National Medical Products Administration for Exdensur (dep...
Insmed reports Phase 2b study of brensocatib did not meet efficacy endpoints
8 April 2026 - Biopharmaceutical company Insmed Incorporated (Nasdaq:INSM) disclosed on Tuesday that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hid...